Associate Director, Medical Affairs, Cutaneous Oncology (CA, NV, HI)
Regeneron Pharmaceuticals
Summary
Regeneron is seeking an Associate Director, Field Medical Affairs responsible for engaging in the exchange of scientific data and other medical and/or scientific information with key opinion leaders (KOLs), health care providers (HCPs), researchers, pharmacists and population-based decision makers. This role demonstrates a thorough understanding of solid tumors, including cutaneous oncology, and other tumors of interest within clinical development and aligned with strategic medical plans.
Job description
When & where
- Location: Field- CA, NV, HI (preference for candidates residing in San Francisco, Los Angeles, or San Diego areas)
- Travel: approximately 50% of the time, including air travel, overnight and occasionally on weekends
Discover your role
- Establish, foster, cultivate and maintain peer relationships with KOLs.
- Act as the primary clinical/scientific resource to HCPs for information pertaining to disease state and our product(s) to ensure awareness and understanding.
- Identifies and maintains a list of relevant medical/therapeutic area experts, investigators and develop engagement plans.
- Support evidence generation (company sponsored trials and investigator initiated studies (IIS)) research initiatives.
- Identify and report medical insights.
- Identifies gaps in research and educational needs to inform medical strategy.
- Responds to requests for information and presents/discusses scientific and clinical data to appropriate audience in a compliant manner.
- Performs disease management and therapeutic area education with identified practitioners, payers and researchers.
- Attends medical conferences to collect and report relevant, scientific, clinical, & competitive intelligence with the purpose of informing internal partners.
- Ensures company policies, procedures, principles and financial controls are maintained with integrity and professionalism is displayed internally and externally.
This role requires
- A terminal scientific degree (MD, PharmD, PhD, DNP or DVM) is required.
- 8+ years of experience with a minimum of 4 years’ experience as an Oncology Medical Science Liaison function is required.
- Knowledge or experience in the Oncology therapeutic area is required, and experience in cutaneous oncology is preferred.
- Established relationships with KOLs in thoracic malignancies and knowledge of institutions focused on Solid Tumor Malignancies preferred.
- Drug launch experience is strongly preferred.
- Knowledge of treatment guidelines, clinical research processes, FDA regulations, pharma regulations/compliant practices, and OIG guidelines.
- Residency in the assigned territory and possession and maintaining a valid driver’s license and clean driving record.
Requirements
- A terminal scientific degree (MD, PharmD, PhD, DNP or DVM) is required.
- 8+ years of experience with a minimum of 4 years’ experience as an Oncology Medical Science Liaison function is required.
- Knowledge or experience in the Oncology therapeutic area is required.
- Experience in cutaneous oncology is preferred.
- Established relationships with KOLs in thoracic malignancies and knowledge of institutions focused on Solid Tumor Malignancies preferred.
- Drug launch experience is strongly preferred.
- Knowledge of treatment guidelines, clinical research processes, FDA regulations, pharma regulations/compliant practices, and OIG guidelines.
- Residency in the assigned territory and possession and maintaining a valid driver’s license and clean driving record.
Benefits
- Annual bonuses
- Incentive plans
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Medical, Dental & Vision
- Life and disability insurance
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.